T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells.
This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the ...
GlobalData on MSN
BMS and Microsoft partner for AI-based lung cancer detection
The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.
The "Electric Vehicle Battery Management System - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The Electric ...
This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.
Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | SAN FRANCISCO—Bristol Myers Squibb is ...
Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...
Pharmaceutical Technology on MSN
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff
BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.
GlobalData on MSN
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...
1d
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
Peter Bains, Managing Director and CEO, Syngene International Ltd., said, "Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback